[Contemporary approaches to the treatment of chronic heart failure in adults (after materials of recommendations of American College of Cardiology and American Heart Association, 2005)].
Detailed and critical analysis of a novel version of the "Updated Guideline for the Diagnosis and Management of Chronic Heart Failure (CHF) in the Adult" prepared by experts of American College of Cardiology and American Heart Association is given. The novel version contains somewhat modified recommendations on the management of patients with CHF. In particular this relates to the place of various classes of drugs in the treatment of CHF due to systolic left ventricular dysfunction. For the first time recommendations on the treatment of patients with CHF and normal left ventricular ejection fraction are presented in detail. Among statements of the updated guideline the following are considered controversial or deserving special discussion. Perindopril is mentioned among recommended ACE inhibitors despite the fact that it has never been studied in long term trials. Results of SENIORS trial are ignored and nebivolol is not included in the number of beta-blockers with proven efficacy. Despite multiple proofs of beneficial effects of aldosterone receptor blockers on clinical course of CHF wide use of spironolactone and eplerenone is not recommended because of multiple communications about life threatening hyperkalemia. Inherent dangers of digoxin therapy are disregarded and the use of cardiac glycosides in patients with sinus rhythm is not prohibited.
Sidorenko
B A
BA
Preobrazhenskiĭ
D V
DV
Batyraliev
T A
TA
Pershukov
I V
IV
Makhmutkhodzhaev
S A
SA
D000368:Aged; D000959:Antihypertensive Agents / Q000145:classification* / Q000627:therapeutic use*; D002309:Cardiology / Q000379:methods* / Q000592:standards*; D017408:Guidelines as Topic; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D014481:United States
D000959:Antihypertensive Agents